• Verapamil HCl in Applied Research: Calcium Channel Blockade

  2026-05-13

  Verapamil HCl is redefining myeloma and arthritis research as a robust L-type calcium channel blocker. Its synergy in apoptosis induction and inflammation models makes it a strategic asset for translational workflows. Discover protocol optimizations, troubleshooting guidance, and cross-study insights for leveraging APExBIO’s high-purity Verapamil HCl in advanced experimental settings.

• Plk1-Mediated Regulation of p31comet in Mitotic Checkpoint D

  2026-05-13

  This study reveals how Polo-like kinase 1 (Plk1) directly regulates p31comet via phosphorylation, modulating the disassembly of mitotic checkpoint complexes (MCC) and preventing premature checkpoint inactivation. These mechanistic insights refine our understanding of cell cycle control and provide a foundation for translational research on mitosis and checkpoint fidelity.

• Q-VD(OMe)-OPh: Transforming Apoptosis Modulation in Translat

  2026-05-12

  Q-VD(OMe)-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) stands at the forefront of apoptosis research, enabling translational scientists to precisely interrogate cell death mechanisms with minimal cytotoxicity. This article synthesizes mechanistic insight, strategic guidance, and real-world validation—including cutting-edge cancer resistance research—to position Q-VD(OMe)-OPh as the gold standard for apoptosis modulation in preclinical and translational workflows.

• Rosemary Extract Disrupts Renal Amyloidosis via Apoptosis Mo

  2026-05-12

  This article examines a multidimensional mechanistic study demonstrating that rosemary extract can disrupt amyloid fibril formation and reduce apoptosis in renal amyloidosis models. The findings reveal modulation of ER stress pathways and restoration of kidney function, providing new mechanistic insight and potential research directions for programmed cell death in amyloid-related diseases.

• Bacterial OMV-Mediated mRNA Antigen Display for Tumor Vaccin

  2026-05-11

  This study introduces a rapid, bacteria-derived outer membrane vesicle (OMV) platform for surface display and delivery of mRNA antigens in personalized cancer vaccines. The engineered OMVs promote efficient dendritic cell uptake, robust T cell activation, and durable antitumor immunity, representing a significant advance over current lipid nanoparticle methods.

• GOB-38 β-Lactamase in Elizabethkingia anophelis: Biochemical

  2026-05-11

  This study characterizes the GOB-38 metallo-β-lactamase from Elizabethkingia anophelis, revealing its broad substrate specificity and structural distinctiveness relative to other MBLs. The findings highlight the enzyme’s potential role in multidrug resistance and interspecies resistance transfer, informing strategies for β-lactam antibiotic resistance research.

• Catalpol Enhances Neurogenesis Post-Stroke via SDF-1α/CXCR4

  2026-05-10

  This study demonstrates that catalpol, a natural iridoid glycoside, significantly improves neurological recovery after ischemic stroke in rats by promoting neurogenesis and angiogenesis through the SDF-1α/CXCR4 signaling axis. These findings clarify catalpol's mechanism in neuroprotection and support its translational potential in ischemic stroke models.

• Lymphodepletion Enhances ACT via Neoantigen Presentation

  2026-05-09

  Sagie et al. demonstrate that lymphodepleting chemotherapy synergistically enhances adoptive cell therapy (ACT) by remodeling the tumor antigenic landscape and increasing neoantigen presentation. Their mechanistic insights reveal that chemotherapy upregulates immunoproteasome activity and HLA-I expression, facilitating improved T cell-mediated tumor recognition and killing.

• Novel 14-3-3 Interactors ATG9A and PTOV1: Mechanisms in Canc

  2026-05-09

  This study identifies ATG9A and PTOV1 as novel 14-3-3 binding proteins and details their mechanistic roles in autophagy and oncogenic regulation, respectively. The findings advance understanding of basal autophagy and protein stability in cancer, with implications for therapeutic targeting and regulated cell signaling.

• Long-Term Degarelix Acetate Use Achieves Effective Chemical

  2026-05-08

  This study demonstrates that repeated administration of Degarelix acetate, a sustainable GnRH receptor antagonist, results in sustained suppression of testosterone and INSL3, testicular atrophy, and complete inhibition of spermatogenesis in male goats. These findings establish a robust model for chemical castration, informing future applications in animal husbandry and endocrine research.

• Applied Strategies for Everolimus (RAD001) in Cancer Researc

  2026-05-07

  Leverage Everolimus (RAD001) to dissect mTOR pathway inhibition with precision across apoptosis assays and proliferation studies. This article delivers optimized protocols, troubleshooting guidance, and actionable insights for translational oncology workflows using APExBIO's high-purity Everolimus.

• Dual Luciferase Reporter Gene System: Precision in Gene Regu

  2026-05-07

  The Dual Luciferase Reporter Gene System enables precise, high-throughput analysis of gene expression regulation by simultaneously measuring firefly and Renilla luciferase activities in a single sample. Discover how APExBIO's kit streamlines transcriptional studies, optimizes normalization, and supports advanced troubleshooting for complex regulatory networks.

• Phenothiazines Boost Macrophage Antibacterial Activity via R

  2026-05-06

  This study demonstrates that phenothiazines, including promethazine hydrochloride, enhance the antibacterial capacity of macrophages by inducing reactive oxygen species (ROS) and autophagy. These host-directed mechanisms offer a promising alternative to conventional antibiotics, particularly against intracellular pathogens and in the context of rising antimicrobial resistance.

• Dual Enzyme-Responsive Zwitterionic Peptides for Cancer Sele

  2026-05-06

  This study introduces a zwitterionic peptide amphiphile engineered for dual enzyme responsiveness, achieving unprecedented cancer cell selectivity via intralysosomal self-assembly. The approach leverages differential enzyme expression to induce selective cancer cell death, with significant implications for the design of targeted peptide therapeutics.

• 3-Bromopyruvate and Cetuximab: Ferroptosis to Overcome CRC R

  2026-05-05

  Mu et al. reveal that co-treatment with 3-bromopyruvate and cetuximab surmounts intrinsic and acquired resistance in colorectal cancer cells by triggering autophagy-dependent ferroptosis. Mechanistic dissection identifies FOXO3a pathway activation as central to this effect, presenting a translational strategy for refractory CRC.

16223 records 1/1082 page Next 12345 下5页 Last page